Clinical Trial Update: DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the combination therapy DZD8586 in patients with Diffuse Large B-Cell Lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• DZD8586

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING